GLOBAL ALLERGY & AIRWAYS PATIENT PLATFORM

HOW PEOPLE WITH COPD PERCEIVE AND COMMUNICATE EXACERBATIONS: A MULTICOUNTRY SURVEY STUDY

Frits ME Franssen 1 , Ruth Young 2 , Job FM van Boven 3 , Michael G Crooks4 , Marie Eckerd 5 , Megan Grobert2 , John R Hurst 6 , Ann Hutchinson 7 , John Linnell 8 , Daiana Stolz 9 , Tonya Winders 10, Jing Zhang 11, Jad El Khoury 12, Clementine Nordon 13

Department of Respiratory Medicine, Maastricht University Medical Centre, Maastricht, the Netherlands; 2 Ipsos Public Affairs, Washington, DC, USA; 3 Department of Clinical Pharmacy and Pharmacology, Groningen Research Institute for Asthma and COPD (GRIAC), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands; 4 Respiratory Research Group, Hull University Teaching Hospitals NHS Trust, Hull, UK; 5 Global Patient Engagement R&I, AstraZeneca, Wilmington, DE, USA; 6 UCL Respiratory, University College London, London, UK; 7 Hull York Medical School, University of Hull, Hull, UK; 8 Patient Author, COPD Foundation, Washington, DC, USA; 9 Clinic of Respiratory Medicine and Faculty of Medicine, University of Freiburg, Freiburg, Germany; 10Global Allergy & Airways Patient Platform, Vienna, Austria; 11Department of Pulmonary and Critical Care Medicine, Zhongshan Hospital, Shanghai Medical College, Fudan University, Shanghai, People's Republic of China; 12Global Medical Affairs – Respiratory, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK; 13Evidence and Strategy – Respiratory, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK

GLOBAL DATA ON COPD AND EXACERBATIONS

COPD EXACERBATIONS:

- are costly for health systems to treat
- severely impact quality of life
- accelerate disease progression
- escalate the risk of cardiopulmonary events

+ symptoms are diverse and non-specific

poorly recognized and under-reported

RESPONDENT PROFILE

857 RESPONDENTS

6 COUNTRIES

50,5% MALE

49.5% FEMALE



EVER HAD AN EXACERBATION

671

NEVER HAD AN EXACERBATION

186



EVER HAD AN EXACERBATION

48 % MALE

52 % FEMALE

NEVER HAD AN EXACERBATION

59 % MALE

41 % FEMALE

BY AGE GROUPS





BY COUNTRIES





COMORBIDITIES





TIME SINCE DIAGNOSIS



INHALER USE

PERCEPTION OF EXACERBATIONS

78% HAVE EXPERIENCED AN EXARCERBATION

> **53%** RECOGNIZE IT AS "WORSE THAN USUAL" SYMPTOMS

> **50%** IDENTIFY IT AS HAVING MORE TROUBLE WITH DAILY ACTIVITIES

ONLY **18%** USE THE WORD **EXACERBATION**



DESCRIBING COPD IN THEIR OWN WORDS





ASSOCIATED EMOTIONS

35%

REPORT A SIGNIFICANT IMPACT OF DAILY SYMPTOMS OF COPD ON THEIR QUALITY OF LIFE

49%
FEEL WORRIED

45%
FEEL FRUSTRATED

34%
FEEL DEPRESSED

DURING EXACERBATIONS

NOT WORRIED

57 %
WORRIED

NOT FRUSTRATED
59 %



FRUSTRATED

KEY TAKE AWAYS

“WHEN DESCRIBING EXACERBATIONS IN THEIR OWN WORDS, PEOPLE LIVING WITH COPD FOCUS ON THE EMOTIONAL IMPACT AND FUNCTIONAL LIMITATIONS OF WORSENING SYMPTOMS HIGHLIGHTING THE NEED TO INCLUDE THESE PATIENT-RELEVANT ASPECTS IN THE ASSESSMENT OF WORSENING EVENTS.”

OUR RESSOURCES ON COPD

www.gaapp.org

@gaapporg